In Q3 FY2022, the gross profit was Rs 23,929 million compared to Rs 23,769 million in Q2 FY2022, with a margin of 58.5 per cent. The personnel cost was 18.2 per cent of sales at Rs 7,438 million compared to Rs 7,586 million in Q2 FY2022. Manufacturing and other expenses were 33.1 per cent of sales at Rs 13,518 million compared to Rs 11,425 million in
Q2 FY2022. Investment in R&D for the quarter was Rs 3,546 million (8.7 per cent of sales).

Nilesh Gupta, MD, Lupin said, “We are on the path of sustained
growth across markets. Our inhalation portfolio continues to build share in the U.S. and helped register double-digit growth sequentially, despite pricing and demand challenges on seasonal products. The inflationary environment has impacted margins, but we remain focussed on margin and EBIDTA improvement as we deliver on key product launches, cost optimization and improving efficiencies, especially by H2 FY23."